Thus, blocking the APC-NKT interaction with an anti-CD1d antibody reduced some aspects of neuroinflammation and neurodegeneration in models of DLB/PD and might be considered as an alternative immunotherapeutical approach for synucleinopathies of the aging population. The gene discussed is CD1D; the disease is synucleinopathy.